Prostatic Neoplasms, Castration-Resistant
41
9
13
17
Key Insights
Highlights
Success Rate
85% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
7.3%
3 terminated out of 41 trials
85.0%
-1.5% vs benchmark
12%
5 trials in Phase 3/4
59%
10 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 17 completed trials
Clinical Trials (41)
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
Development and Prospective Validation of a Pathology-Based Artificial Intelligence Model for Predicting the Time to Castration Resistance of Prostate Cancer
Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer
Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
HTL0039732 in Participants With Advanced Solid Tumours
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)